Given that mesothelioma is such an aggressive cancer, it is always exciting when new treatments are discovered.
CAR-T cell immunotherapy is a newer approach to cancer treatment that works to modify a patient’s white blood cells in hopes that they will attack and destroy cancer cells. When a T cell finds the antigens of a cancer cell, it triggers the entire immune system to fight back. By capturing a patient’s T cells and altering them to seek out a specific cancer cell and reintroducing them to the patient, CAR-T cell immunotherapy can help to laser focus the body defending itself. Your immune system could be trained to go right after the specific cells in a pleural malignant mesothelioma tumor.
It may be a huge advancement in cancer treatment, and Bayer and Atara have teamed up to improve CAR-T cell immunotherapy through further research and development. Together, they hope to bring more of this technology to market.
“This exciting collaboration between Atara and Bayer will accelerate the development of mesothelin-targeted CAR T-cell therapies for multiple solid tumors and helps us advance the power of our allogeneic cell therapy platform to patients as quickly as possible,” said Pascal Touchon, President and CEO Atara.
Their new agreement directly addresses working with ATA2271, an autologous T cell aimed at tumors with high levels of mesothelin such as malignant pleural mesothelioma.
For more information about mesothelioma treatments and to learn more about next steps if you’ve been diagnosed, reach out to one of our specialists at the Mesothelioma Help Organization today.